SIETES :: 92565 citas

Resultados de la búsqueda por BIOTECNOLOGÍA REFINAR BÚSQUEDA

1.

Sinha MS, Curfman GD, Carrier MA. Antitrust, market exclusivity, and transparency in the pharmaceutical industry. JAMA 2018;319:12 de junio. [Ref.ID 102779]

2.

Anónimo. Atézolizumab et cancer bronchique métastasté ou inopérable. Prescrire 2018;38:503-4. [Ref.ID 102758]

3.

Anónimo. Inotuzumab ozogamicine et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:494-9. [Ref.ID 102757]

4.

Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]

5.

Anónimo. Bill And Melinda Gates build A “biotech-within-a-charity”. DIA Daily 2018:1. [Ref.ID 102662]

6.

Anónimo. Alectinib et cancers bronchiques ALK-positifs. Prescrire 2018;38:337-9. [Ref.ID 102653]

7.

Maya Y, Ota M. Drug-induced localised scleroderma. BMJ 2018;360:12 de abril. [Ref.ID 102643]

8.

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, opportunities, and reality of biosimilar medications. N Engl J Med 2018;378:24 de mayo. [Ref.ID 102636]

9.

Tsourdi E, Rachner TD, Hofbauer LC. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102629]

10.

Lewis JR, Schousboe JT, Prince RL. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102628]

11.

Song GG, Lee YH. Romosozumab versus alendronate and fracture risk in women with osteoporosis. N Engl J Med 2018;378:11 de enero. [Ref.ID 102627]

12.

Anónimo. Atezolizumab: Myocarditis. Canada. WHO Drug Information 2018;32:19. [Ref.ID 102622]

13.

Feuerstein A. After watching Trump’s drug speech, investors poured big money into biotech funds. STAT Daily Recap 2018:4. [Ref.ID 102605]

14.

Anónimo. Blinatumomab et leucémie aiguë lymphoblastique chez les adultes. Prescrire 2018;38:97-9. [Ref.ID 102582]

15.

Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, Wang A. Anti–tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. JAMA Neurology 2018;75:939-46. [Ref.ID 102569]

16.

Anónimo. EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta. European Medical Agency 2018:7 de marzo. [Ref.ID 102551]

17.

Darrow JJ, Avorn J, Kesselheim AS. The FDA breakthrough-drug designation - Four years of experience. N Engl J Med 2018;378:16 de abril. [Ref.ID 102515]

18.

Anónimo. Drugs and their names. Drug Ther Bull 2018;56:marzo. [Ref.ID 102507]

19.

Anónimo. Roche denies Hemlibra caused deaths of five patients, share prices fall. DIA Daily 2018:12. [Ref.ID 102487]

20.

Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: a retrospective cohort study. Br J Clin Pharmacol 2017;84:1. [Ref.ID 102184]